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Precision MedicineThis article characterizes the opinions of patients and family members of patients undergoing clinical genomic-
based testing regarding the return of incidental ﬁndings from these tests. Over sixteen months, we conducted
55 in-depth interviews with individuals to explore their preferences regarding which types of results they
would like returned to them. Responses indicate a diversity of attitudes toward the return of incidental ﬁndings
and a diversity of justiﬁcations for those attitudes. The majority of participants also described an imperative to
include the patient in deciding which results to return rather than having universal, predetermined rules
governing results disclosure. The results demonstrate the importance of a patient centered-approach to returning
incidental ﬁndings.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Individualizedmedicine promises that with a patient's genomic pro-
ﬁle, clinicians will be better able to diagnose and tailor treatments, ulti-
mately leading to improved health outcomes and resource utilization.
However, genomicmedicine foregrounds issues of return of unexpected
results, known as incidental ﬁndings (IFs), from such tests. As we devel-
op policies for the future of genomicmedicine, wemust determine how
to incorporate patients' values and expectations in a meaningful and
ethically robust way.
At this early stage of genomic translational research, it is often un-
clear whether data generated have clinical signiﬁcance. A number of
studies have examined research participants' expectations and attitudes
toward the return of individual research results with potential clinical
signiﬁcance (Beskow et al., 2009; Kaufman et al., 2012; Ormond et al.,
2010; Rigter et al., 2013a,b; McGowan et al., 2013; Daack-Hirsch et al.,
2013; Townsend et al., 2012; Clarke, 2014; Fernandez et al., 2014;
Sapp et al., 2014; Facio et al., 2013; O'Daniel and Haga, 2011; Shalowitz
and Miller, 2008). These studies show that research participants want
genetic data returned to them. Other studies reveal that many research
participants want all of these data regardless of its clinical signiﬁcance
or “actionability” (Bollinger et al., 2013; Harris et al., 2013). Most of
these studies were conducted with individuals participating in genomic
research studies rather than undergoing clinical genome or exomeer 3-30-40 Bioethics, Rochester,
0850.
ick).
. This is an open access article undersequencing. This distinction – research versus clinical – is sometimes
pointed out as justiﬁcation for not necessarily returning a genetic inci-
dentalﬁnding unless it reaches a high threshold of urgent clinicalmean-
ing (e.g. malignant hyperthermia) (Fabsitz et al., 2010). There have
been efforts to ‘bin’ ﬁndings into various categories based on clinical
utility, actionability, and clinical urgency (Berg et al., 2011, 2013;
Lindor et al., 2013; Bradbury et al., 2014a; Goddard et al., 2013). Some
attempts have been made to distinguish between clinical actionability
and personal utility (Bunnik et al., 2014) as well as to describe how
the general, non-medical public understand and articulate these terms
(Graves et al., 2015). While scholars have been discussing the return
of incidental ﬁndings for more than a decade, (Jarvik et al., 2014; Wolf
et al., 2013; Green et al., 2013a; Fullerton et al., 2012; Biesecker, 2013)
the debate has intensiﬁed with the increasing clinical use of exome se-
quencing (Green et al., 2013a,b; Fullerton et al., 2012; Bradbury et al.,
2014b; McGuire et al., 2013; Ross et al., 2013; McCormick et al., 2014;
Yu et al., 2014).
We present results from a qualitative study in which we conducted
interviews with patients and family members of patients pursuing
exome sequencing in a clinical setting. Our results represent one of
the ﬁrst studies to demonstrate the range of patients' opinions andmo-
tivations for those opinions in a clinical setting. Patients expressed a va-
riety of preferences for learning incidental ﬁndings from genomic
sequencing; however, regardless of the differences they had in personal
preference, most agreed that individual choice and participation in the
decision making process was critical. These ﬁndings highlight the
importance of a patient-centered approach to returning ﬁndings from
clinical exome sequencing. By recognizing how patients' perspectivesthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
39K.E. Clift et al. / Applied & Translational Genomics 4 (2015) 38–43differ or coincide with those of medical experts (e.g., clinical laborato-
ries, professional organizations, healthcare institutions, and providers),
it becomesmore feasible to develop policies that are capable of respect-
ing all concerns salient to patients during healthcare decision-making.
2. Methods
2.1. Study design and participants
The studywas designed to investigate patient attitudes toward geno-
mic medicine. Interview guides and participant contact materials were
developed and subsequently approved by the Mayo Clinic Institutional
Review Board. We conducted in-depth, semi-structured interviews
(Britten, 1995) with patients and their family members engaged in the
process of utilizing exome sequencing as a tool for clinical diagnosis or
treatment at the Mayo Clinic Individualized Medicine Clinic (IM Clinic).
The IM Clinic was established to integrate new sequencing technologies
into medical practice (Lazaridis et al., 2014). Patients referred to the IM
Clinic during the time of this study either had a cancer that had failed
standard treatments or were going through a “diagnostic odyssey,”
that is, pursuing diagnosis after having exhausted all standard available
limited gene panel tests relevant to their phenotype. Diagnostic odyssey
participants presented with a range of phenotypes, including those that
affect respiratory function, digestion, the musculoskeletal system, the
brain and nervous systems, others included immunodeﬁciencies, or de-
velopmental delay. Oncology participants represented a variety of can-
cers including breast, colon, gastrointestinal, ovarian, kidney, liver,
lung, brain, and a number of rare cancers.
Clinical laboratory companies that provide clinical exome sequenc-
ing have their own sets of guidelines for the return of incidental ﬁndings
(Jamal et al., 2013). The guidelines of the clinical laboratory that the IM
Clinic used at the time of this study were reviewed with the patient
during the genetic counseling session.
2.2. Data collection
Individuals were invited to participate in this study after they had
their initial appointmentwith an IMClinic physician. Interested individ-
uals were consented and granted permission for the researchers to ac-
cess their conﬁdential health information by signing a HIPAA form.
Interviews began in December 2012 and concluded in March 2014
andwere done either in person or by telephone, depending on the indi-
vidual participant's preference. Interviews were conducted by KEC
(medical anthropologist), CMEH (linguistic anthropologist), and JBMc
(molecular biologist trained in empirical bioethics and policy). Inter-
views lasted between 10 and 50 min, with a mean time of 20 min. We
interviewed patients and family members at one or more of four points
during the course of their interactionwith the IM Clinic.We talkedwith
a number of participants before their initial meeting with the genetic
counselor, after that meeting, during the waiting period for testing
and analysis, and after the return of testing results. The purpose of
conducting multiple interviews was to see how various interactions –
with the genetic counselor, with family and friends, and after receiving
results – might change their opinions and beliefs regarding testing.
There were many complications that prevented us from conducting
interviews with the same people at each of these time points. Those
complications included attrition due to insurance coverage, health
issues, and the often-spontaneous nature of referrals. As exome
sequencing can take nearly half a year for results to be returned, we
also interviewed many of the participants during the waiting period to
gauge attitudinal change. Timing of the interviews depended on the
situational context, in particular the availability and health status of
the participant.
The team developed an interview guide consisting of four to six
open-ended questions, depending on the stage of the process at which
the participant was interviewed (interview guides available uponrequest). All questions included follow-up probes that were used as
needed. The interview guide was modiﬁed iteratively as data were col-
lected and analyzed and new themes emerged as salient. The general
domains covered by the questions included general understanding of
genomics and exome sequencing, expectations versus hopes, con-
cerns and challenges, and access to results and incidental ﬁndings.
Questions probed participants' perspectives on choosing whether
to learn clinically actionable incidental ﬁndings, optional informa-
tion like carrier status or pharmacogenomic relevance, and risk for
adult-onset dementias. For the purposes of this paper we have
chosen to use the general term “incidental ﬁndings” (Presidential
Commission for the Study of Bioethical Issues (PCSBI), 2013)
for terms related to any additional anticipated, unanticipated,
secondary, or discovery ﬁndings from the application of exome se-
quencing for diagnostic or treatment purposes.
When interviews included more than one participant – for example
a cancer patient undergoing the sequencing and her spouse, or both
parents of a diagnostic odyssey patient – all participants consented to
be interviewed and signed a HIPAA form.Whenwe hadmultiple partic-
ipants in an interview, it was at the request of the participants. Each
question was posed to all participants in the group interview. By the
conclusion of interview collection, theoretical saturation was achieved
for the purposes expressed in the themes of this paper.
2.3. Data analysis
Audio-recordings of the interviews were transcribed, de-identiﬁed,
and analyzed using standard qualitative methods. All data were stored
on a secure server. Team members read the transcripts, and based on
this initial review, a coding scheme was developed. A codebook was
constructed using aspects of grounded theory and inductive qualitative
analysis, which allowed unanticipated themes to emerge from the data
(Corbin and Strauss, 2008). At least two study teammembers analyzed
all transcripts, independently using the scheme, and discrepancies were
resolved through discussion reaching consensus. The coded text was
then compiled for further narrative and manuscript development. The
data were analyzed using the standard qualitative data analysis soft-
ware, QSR NVivo 10.
3. Results
During the timeframe of this study, the IM Clinic had 95 oncology
patient referrals and 75 diagnostic odyssey referrals. Individuals
representing 37 IM Clinic cases (19 odyssey/18 oncology) were recruit-
ed and participated in the study andwere interviewed at least once. Rel-
ative to participant availability, some were interviewed as many as
three times. A total of 55 interviews were conducted. Here we deﬁne
cases to include patients as well as family members, noting that one
case had as probands two siblings with the same genetic condition.
Sixteen cases had at least one follow-up interview. The oncology
patients interviewed ranged in ages from 29 to 67 years (7 males and
11 females). In some oncology cases, family members joined in the in-
terviews at the request of the proband. Such group interviews were
counted as a single interview. The diagnostic odyssey participants
were more often parents of the proband, but seven patients, who
were old enough and cognitively able to participate, were interviewed
individually, though family members occasionally joined at the request
of the proband. The diagnostic odyssey patients ranged in age from
20 months to 45 years (12 females and 8 males) (see Table 1). Six of
the cases interviewed (three diagnostic odyssey/three oncology) did
not proceed with exome sequencing after the initial genetic counseling
appointment because of lack of insurance coverage, ineligibility for
exome sequencing, or they were not a candidate for surgery for sample
acquisition. Twelve of the participants were interviewed after they
received their results (7 diagnostic odyssey, and 5 oncology). Indi-
viduals are identiﬁed as either diagnostic odyssey (Dx) or oncology
Table 1
Participant information.
Oncology Diagnostic odyssey
Age range of the proband 29 years–67 years 20 months–45 years
Gender (male/female) of the proband 7/11 8/12
Total interviews 30 25
Total cases 18 19 (1 case included siblings as probands)
Did not proceed with exome sequencing 3 3
Interviewed after results were returned 5 7
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Male).
Many participants expressed that they would not like to receive any
ﬁndings from exome sequencingwhichwere irrelevant to their current
condition. Motivations driving this preference were varied, and includ-
ed religious or personal beliefs, burden of information, anxiety and
worry, and concerns about insurance repercussions. In contrast, some
wanted to know everything, even if such knowledge would not change
treatment. Others believed that having more knowledge about health
risks would be valuable to alleviate uncertainty, discover answers, pro-
vide information for family members, take preventative measures, in-
sure quality of life, and participate in research. Participants often
discussed the importance of choice and their ability to decide which re-
sults to learn. We organize these data under three broad domains:
(i) wanting to know, (ii) wanting not to know, and (iii) patient choice.
Theﬁrst two domains represent the potential diversity of personal opin-
ions, while the third demonstrates the nearly unanimous belief that all
participants are entitled to their own choice and that any choice differ-
ent from their own should nonetheless be treated with respect.
3.1. Wanting to know
Many patients voiced a desire to receive incidental ﬁndings. These
participants believed that knowledge of incidental ﬁndings could im-
prove their quality of life, aid in their search for answers, and help
them to prevent or at least to prepare for future health issues.
3.2. Quality of life
Certain participants felt that the beneﬁts of having access tomore in-
formation outweighed the burdens associated with that knowledge.
When prompted with speciﬁc results that have limited or no clinical
utility, including variants that indicate a risk for a condition for which
no known treatment currently exists, the patients restated that they
would like to know. As outlined in Table 1, the IM Clinic currently uses
a laboratory that does not return incidental ﬁndings related to adult-
onset neurological conditions that are not currently clinically action-
able. Despite this, some participants in our study considered such re-
sults ‘actionable’ in other areas of their lives. Several participants were
disappointed when they found out that they would not have the option
to learn that information. One patient's mother asked:
“If I know she's going to develop Alzheimer's or some future degen-
erative neurological disorder, do I put her through chemo so she can
wait to suffer that? I think treatment is always preserving the ability
to access some future quality of life. […] I felt that informationwould
be important in helping us to determine how far to go with treat-
ment. […] It is actionable information. For us, for our family, it's
actionable.” (Mother of Dx18yF)
According to this mother, the prohibited information, which the
laboratory had deemed non-actionable, would in fact be useful in
making treatment decisions for her daughter.
Another participant described how knowledge from exome se-
quencing could be used to impact her own quality of life:“I would like to know anything that could possibly impact the rest of
my quality of life. […] Having an undiagnosed chronic disease since
youwere a little child, you don't know how to plan things. […] If you
don't know how day-to-day life is going to go, you never know
exactly what could be coming next.” (Dx20yF)
3.3. Finding answers and preparing for the future
Participants repeatedly expressed a desire for information that
might illuminate any aspect of their health care now or in the future.
Participants recognized that exome sequencing inevitably uncovers var-
iants of uncertain signiﬁcance (VUSs) that may lead to more questions
without providing any answers. One patient's mother described VUSs
as potentially “another step forward in someday ﬁnding an answer”
(Mother of Dx14yM).
Participants speculated that there are other areas in their lives in
which they could put genomic data into action. Several mentioned
that they would use any information to help prepare for the future.
One participant elaborated:
“I feel like knowing that information can just helpmeplan for the fu-
ture […] Maybe there are some lifestyle changes I could make that
could beneﬁt me. I think I would want to know […] even if there is
no treatment […] to possibly plan for long-term care.” (Dx42yF)
Some oncology patients stated that other ﬁndings unrelated to their
cancer would be helpful in planning their lives. Equally comforting for
some was the fact that more information gave them a sense of control.
As this participant stated:
“I think information is power […] It affects your family, home, your
children; I mean, it affects everything. […] The more you know, the
better off you're going to be.” (O57yF)
One participant explained that he would like to be able to learn the
variants for untreatable conditions so that he could make sure he was
not a burden for his loved ones. He said, “I want to know, because it's
going to affect how I live my life, and make sure that I have everything
in order, so that I am as little of a burden as I can be if it does happen.”
(O65yM)
In addition, a few patientsmentioned that if they could know results
related to untreatable conditions, they would participate in research to
help ﬁndways to prevent or treat the condition. The father of a diagnos-
tic odyssey patient put it this way: “It is an opportunity for us to learn
more about [the patient] that might beneﬁt her and also beneﬁt other
people” (Father of Dx5yF).
One of the daughters of an oncology patient expressed her hope that
they could contribute to future research and be a part of the process of
discovery: “Who knows what they are going to discover soon, and so,
if you know about it now, you know, you can always be watching
[and] participate in studies” (Daughter of O67yM).
After receiving her non-deﬁnitive results from sequencing, one
patient began a petition with others who share her rare disease
in order to raise the funds for more research to be done. She
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empowering” (Dx45yF).
3.4. Wanting not to know
As discussed in the previous section, patients often expressed a
desire to receive results that are not typically returned. However,
many participants also expressed a desire not to learn certain types
of IF. These participants explained that the burden of learning addi-
tional information would outweigh any beneﬁt of knowing those
results.
3.5. Religious beliefs
Some participants highlighted religious beliefs against learning
incidental information. For example, regarding the option to learn her
daughter's carrier status, one mother ruminated:
“So that means her future spouse would have to be a carrier, and
then religiously with our beliefs, we wouldn't do anything with that
anyhow. Is that knowledge really necessary? That was a difﬁcult one
for me.” (Mother of Dx17yF)
Another example of how personal and religious beliefs inﬂuence
such decisions was the view that we are not meant to know certain
things. As one patient suggested:
“I just question:With our religion or beliefs […] are we supposed to
know that I'm going to have Alzheimer's in another 50 years? I don't
know if I'm supposed to know that. […] I don't thinkweweremeant
to knowwhat will happen and what we are going to be given in our
life.” (O34yF)
In both these instances, religious beliefs were given as a reason to
decline disclosure of certain results. Although both interviewees were
party to an active search for speciﬁc genetic information, they wanted
explicitly to avoid other (unrelated) information.
3.6. Burden of knowledge
Several other participants articulated similar perspectives about
learning indicators for their future health but without the religious
framing. For these patients there was a pragmatic concern about
undue stress.
“I don't know if I even want to know this, honestly. […] It's like,
I don't go to a palm reader, either, so they can tellmewhatmy future
is going to be. I don't want to know that, because then you worry
about it.” (O41yF)
Participants were concerned that incidental information would
cause additional anxiety. One participant expressed that “not knowing
might even be a blessing” (O61yF). And another thought that learning
anything other than a potential targeted treatment was “irrelevant”
(O64yM). He mentioned that if his healthcare team found a treatment
and his condition improved, he might want to know, but that was not
his focus or his goal at the moment.
A few parents of diagnostic odyssey patients did not want to learn
other ﬁndings, especially regarding results such as adult-onset neuro-
logical dementias. They did not want the additional worry and were
thankful that this had not been an option provided. According to one
mother, such information would be a “ticking time bomb” (mother
of Dx6yM). Along similar lines, another participant explained, “It
would cause more anxiety. Worrying about him having Alzheimer's
in sixty to seventy years would just be more detrimental to the waywe would treat him. […] I wouldn't want to know that” (Mother of
Dx14yM).
3.7. Future repercussions
Some patients were concerned with how the incidental information
would affect insurance eligibility and coverage in the future. One partic-
ipant explained:
“The biggest concern I have is down the line, in the future, how this
may affect my children with insurance, you know, conﬁdentiality.
[…] You never know what the future is going to hold for our
healthcare and insurance companies and payment and jobs, and
[whether it is] going to be used to be discriminated against with
my children.” (Dx45yF)
In fact, several othersworried about privacy and insurance repercus-
sions for their children or other family members in the future. Voicing
these concerns, one of the participants noted:
“It is going to open a can of worms. Let's say that the genetic se-
quence of my tumor shows a predisposition to a terminal situation
that I don't even know that I have. […] Are insurance companies
going to deny treatment based on DNA sequencing?” (O61yF)
Though patients elected to participate in genomic testing for their
indication, some were wary that any incidental information revealed
in the process could potentially raise considerable risks for insurance
coverage in the future and that it could lead to unnecessary anxiety.
3.8. Patient choice
Therewas a general belief that individuals should be allowed greater
involvement in deciding which results they would receive. They
respected that some individuals do not want to learn anything more
than necessary for their presenting condition. On the other hand, they
recognized that others might want as much information as possible.
Furthermore, many participants explicitly stated that patients with
different opinions should be allowed to make their own decisions.
Some participants expressed a sense of inherent ownership of their
genomic information and presented this as the basis for their right to de-
cide what they do and do not learn. For example, one woman noted,
“You feel like if there is information out there that somebody ﬁnds out
about your genes, you should have the right to know it, right? You
should have the choice because it is yours” (Mother of Dx6yM).
Regardless, participants recognized that making decisions about
what to learn or not to learn should not be taken lightly, as this partici-
pant thoughtfully articulated:
“I absolutely believe this is all about choice. […] It has potential to be
a great choice, but yet it may tell me more than I am comfortable
knowing right now. So I think it is absolutely a choice and it is all
about the choice, but it doesn't mean it is an easy choice.” (Husband
of O34yF)
Considering that this participant and his wife, the patient, were not
interested in learning incidental ﬁndings that were irrelevant to the
patient's presenting condition and treatment, choice itself was notably
important regardless of their current opinions. One participant, who
was disappointed that she would not learn ﬁndings related to
untreatable dementias, fervently asserted that people should be able
to have a choice:
“I don't think you can make a blanket legislation like that. I don't
think you can blanket people like that. I think this is the Individual
Medicine program for a reason. Everything has to be on a case by
case by case basis because this is serious information and there are
many patients who could not handle that information. […] I think
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tion of a medical geneticist. I would never want someone else to de-
cide that for me.” (Dx20yF)
As this participant advocated, the individual context and patient's
individual preferences should be central to the practice of individualized
medicine.
4. Discussion
Though there was considerable diversity of nuanced opinions in our
study's population regardingwhat should or should not be returned, the
importance of personal choice and participation in the decision was ar-
ticulated by a majority of our participants. In addition to these ﬁndings,
our research provides novel data for why individuals in a clinical setting
desire to be able to choose not to receive certain results. These data help
clarify why it is critical to allow patients to opt out of receiving certain
results (American College of Medical Genetics and Genomics (ACMG),
2014).
Anecdotally, it is not uncommon to hear from clinicians the assump-
tion that a diagnostic odyssey patient will want to learn all results from
genetic testing, because these tend to be patients seeking answers. They
are assumed to want any and all information they can obtain. On the
other hand, oncology patients are regularly assumed to have focused
concerns on only their current malignancy. Our data however, indicate
that this is not always the case. Our ﬁndings demonstrate that even
within these two different patient populations there is diversity in
views about what is important to learn or not learn from genomic
testing.
Participants felt that as the individuals who are impacted by the ge-
netic ﬁnding, they should have a voice in decisions about what results
are returned. We heard several patients express frustration about
their not being able to receive ﬁndings they believed would be useful
for them. In their opinion, incorporating notions of personal utility
into decisions about what to return is as important as considerations
of clinical utility. This particular ﬁnding points to a possible tension be-
tween patients' values and regulatory policies implemented in a one-
size-ﬁts-all approach. More empirical research is needed to describe
howpatients and their families, health care providers, and even insurers
distinguish and apply the notion of personal utility.
While our study offers rich, qualitative data regarding participants'
opinions on the return of incidental ﬁndings from genomic testing, it
does have limitations. First, we conducted a limited number of inter-
views. An in-depth interviewmethodwas used, and therefore the num-
ber of participants was limited. Further studies, both qualitative and
quantitative, are needed to gather additional empirical data. While our
goal was to interview participants at multiple time points during their
journey through the IM Clinic, this was not uniformly achieved due to
the health of participants and loss to follow-up. Due to the timing of
the study, there was a limited number of participants who were
interviewed after the return of testing results (see Table 1). Prior to
being interviewed, many of our participants had undergone at least
one genetic counseling session about what would be returned from
genomic sequencing; this knowledge may have inﬂuenced their
responses. Ideally, all participants would have been interviewed prior
to their ﬁrst encounter with an IM Clinic genetic counselor. However,
this goal was not achieved, as referrals to the IM Clinic were often spon-
taneous and therefore there was variability in when participants could
be recruited. There was also variability in when the interviews were
conducted during the process, as many participants traveled to Mayo
Clinic from distant locations and the interviews were set up according
to the convenience of the participants, either when they were at Mayo
Clinic for other appointments or when they were available via tele-
phone. Not all the participants in the group interviews participated in
the follow-up interviews, as these were often conducted over the
phone with the proband or parent of the minor proband. Althoughour participants represented patients who both agreed to and declined
testing, more research should be done in order to evaluate how
the trends demonstrated in our data correspond to preferences in
other populations, particularly in populations with less critical health
concerns.
Despite our limited sample, our data imply that shared decision
makingmay need to be better integrated into the delivery of clinical ge-
nomic technologies. Shared decision making in health care delivery has
received increased attention in the last several years, and several groups
have demonstrated how appropriate uses of shared decision making
can improve health outcomes and healthcare delivery overall (Stacey
et al., 2014). Within this context, being sensitive to how to deliver ge-
netic ﬁndings to patients is also critical, especially if the patient has
expressed a desire to remain focused only on his/her current condition.
We know much about what patients and research participants think
they want to learn. More data are needed to understand the diversity
of reactions frompatients undergoing exome sequencing and their fam-
ilies upon learning about additional, potentially devastating, genetic
risks.
Patients' perspectives of risks and beneﬁts of knowing genomic
information are personal and contextual. It will be important to contin-
ue examining the diversity of patients' and other stakeholders' perspec-
tives as genomic technologies are increasingly used in the clinical care.
Empirical studies like the one we describe here are critical to ensuring
that the translation of genomic technologies into clinical practice
happens in a socially and ethically responsible manner.Acknowledgments
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